Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
abus · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$8.50
Consensus
$8.50
+100.5% upside
Low
$8.50
Median: $8.5 · Last Close: $4.24
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.18 | ↓ 1.39% |
1-day model range: $4.16–$4.2. Peak: $4.2 (-1.39%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $6 | +32.1% |
| 2028 | $7 | +55.4% |
| 2029 | $7 | +70.5% |
| 2030 | $8 | +79.6% |
| 2031 | — | +84.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ABUS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Chardan Capital | Maintains | Buy→Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-28 | Chardan Capital | Maintains | Buy→Buy |
| 2025-01-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-20 | Chardan Capital | Maintains | Buy→Buy |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-06 | Chardan Capital | Maintains | Buy→Buy |
| 2024-09-05 | Jefferies | Maintains | Buy→Buy |
| 2024-08-02 | JMP Securities | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Arbutus Biopharma Corporation (ABUS) stock. Of the recent 67 rating actions, 11 were upgrades and 7 were downgrades. 10 analysts currently cover ABUS.
Analyst Recommendation Trends
ABUS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$14M
↑ 404.8% YoY
Revenue Next Year
$91M
↑ 568.4% YoY
EPS This Year
$-0.19
EPS Next Year
$0.29
↓ 257.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast ABUS EPS of $-0.19 for the current fiscal year, based on estimates from 1 analysts. The ABUS revenue forecast is $14M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ABUS stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ABUS price target is $8.50 (+100.5% upside), with an analyst consensus of Buy.
The ABUS short-term stock prediction for tomorrow is $4.18 (-1.39%). The ABUS stock price prediction for 2027 estimates an average of $6. The ABUS stock prediction for 2030 projects a range of $7–$8.
Arbutus Biopharma Corporation trades on NASDAQ under the ticker ABUS. The ABUS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
ABUS forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month ABUS price target is $8.50, with a high forecast of $8.50 and a low of $8.50. The median price target is shown in the chart above when available. This implies +100.5% potential upside from the current price of $4.24.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.